FSA Wealth Management LLC Purchases Shares of 427 Zoetis Inc. (NYSE:ZTS)

FSA Wealth Management LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, Holdings Channel.com reports. The firm acquired 427 shares of the company’s stock, valued at approximately $83,000.

A number of other institutional investors also recently made changes to their positions in the company. Cetera Investment Advisers grew its stake in shares of Zoetis by 275.2% in the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after acquiring an additional 70,476 shares in the last quarter. Simplify Asset Management Inc. bought a new stake in Zoetis in the 3rd quarter valued at about $11,684,000. Bank Pictet & Cie Asia Ltd. grew its position in shares of Zoetis by 41.0% during the 2nd quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock worth $6,501,000 after purchasing an additional 10,900 shares in the last quarter. Swedbank AB increased its holdings in shares of Zoetis by 56.2% during the second quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock worth $337,407,000 after purchasing an additional 700,398 shares during the period. Finally, B&L Asset Management LLC bought a new position in shares of Zoetis during the third quarter worth approximately $563,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.8 %

Shares of NYSE ZTS opened at $175.25 on Monday. The stock has a 50-day moving average price of $183.83 and a two-hundred day moving average price of $180.97. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a market cap of $79.07 billion, a price-to-earnings ratio of 32.94, a PEG ratio of 2.69 and a beta of 0.89.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.36 EPS. As a group, analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.99%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus increased their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research raised their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.